MiR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Liu, Angela M ^a,e   Xu, Zhi ^c   Shek, Felix H ^e   Wong, Kwong Fai ^d   Lee, Nikki P ^e   Poon, Ronnie T ^e   Chen, Jinfei ^c   Luk, John M ^a,b,c,d,e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c NANJING MEDICAL UNIVERSITY   (China)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA 122; PYRUVATE KINASE M2 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANAEROBIC GLYCOLYSIS; ARTICLE; CANCER CELL; CELL METABOLISM; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; ONCOGENE; OXYGEN CONSUMPTION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PYRUVATE KINASE M2 GENE; REGULATORY MECHANISM;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GLYCOLYSIS; HUMANS; IMMUNOENZYME TECHNIQUES; LACTIC ACID; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXYGEN CONSUMPTION; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; THYROID HORMONES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84899816282     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086872     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA: a cancer journal for clinicians 61: 69-90.
2. Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, et al. (2010) microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Molecular systems biology 6: 402.
3. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, et al. (2012) MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. The Journal of clinical investigation 122: 2884-2897.
4. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, et al. (2009) MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49: 1571-1582.
5. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, et al. (2009) MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. The Journal of biological chemistry 284: 32015-32027.
6. Boutz DR, Collins PJ, Suresh U, Lu M, Ramirez CM, et al. (2011) Two-tiered approach identifies a network of cancer and liver disease-related genes regulated by miR-122. The Journal of biological chemistry 286: 18066-18078.
7. Warburg O (1956) On the origin of cancer cells. Science 123: 309-314.
8. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
9. Liu LX, Lee NP, Chan VW, Xue W, Zender L, et al. (2009) Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology 50: 1453-1463.
10. Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, et al. (2011) AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 30: 1229-1240.
11. Liu AM, Poon RT, Luk JM (2010) MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochemical and biophysical research communications 394: 623-627.
12. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, et al. (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115: 4576-4585.
13. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, et al. (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233. (Pubitemid 351380249)
14. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS (2009) Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28: 3526-3536.
15. Jung CJ, Iyengar S, Blahnik KR, Ajuha TP, Jiang JX, et al. (2011) Epigenetic modulation of miR-122 facilitates human embryonic stem cell self-renewal and hepatocellular carcinoma proliferation. PLoS One 6: e27740.
16. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, et al. (2009) Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Science signaling 2: ra73.
17. Lv L, Li D, Zhao D, Lin R, Chu Y, et al. (2011) Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Molecular cell 42: 719-730.
18. Kitamura K, Hatano E, Higashi T, Narita M, Seo S, et al. (2011) Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. Journal of hepatology 55: 846-857.
19. Sun Q, Chen X, Ma J, Peng H, Wang F, et al. (2011) Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proceedings of the National Academy of Sciences of the United States of America 108: 4129-4134.
20. Yang W, Xia Y, Hawke D, Li X, Liang J, et al. (2012) PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150: 685-696.
21. David CJ, Chen M, Assanah M, Canoll P, Manley JL (2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463: 364-368.
22. Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, et al. (2011) Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334: 1278-1283.
23. Chaneton B, Gottlieb E (2012) Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends in biochemical sciences 37: 309-316.
24. Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, et al. (2010) Identification of small molecule inhibitors of pyruvate kinase M2. Biochemical pharmacology 79: 1118-1124.
25. Walsh MJ, Brimacombe KR, Veith H, Bougie JM, Daniel T, et al. (2011) 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorganic & medicinal chemistry letters 21: 6322-6327.